- OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’
- Bio-Rad Launches Celselect Slides 2.0 to Advance Rare Cell and Circulating Tumor Cell Enrichment for Cancer Research
- VenoStent Completes $20 Million Series A with $4 Million Investment from Norwest Venture Partners
- PharmaEssentia Completes Patient Enrollment for Phase 2b EXCEED-ET Trial in Essential Thrombocythemia and Phase 3b ECLIPSE-PV Trial in Polycythemia Vera
- Dr Fred Cohen: Higher Temperatures Trigger Migraines According to New Study
- Qure.ai Reports Strategic Investment by Merck Global Health Innovation Fund to Boost Innovation of Healthcare AI
Medical Device News Magazine is a digital Publication Founded in 2008, and proudly located in the United States
Medical Device News Magazine has established itself as one of the foremost and most trusted sources of comprehensive updates and insights within the medical device and biotech industries. Our publication is committed to delivering timely and relevant information, making it a go-to resource for professionals and enthusiasts alike.
Medical Device News Magazine is easily accessible to readers 24/7/365, allowing you to stay informed at your convenience, and it presents content that is a fast and engaging read. We take pride in offering valuable insights in a format that can be consumed quickly, ensuring that our audience stays ahead of the curve.
Furthermore, if you are interested in expanding your reach and visibility within this dynamic field, we encourage you to inquire about advertising opportunities with us.
"Medical Device and Biotechnology Sector News: Essential Key Insights and Noteworthy Developments that are Shaping the Future"
Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM
The Tandem Mobi Insulin pump is small enough to be worn almost anywhere, including a coin pocket, providing users with more discretion, comfort, and options for how they manage their diabetes. Powered by Control-IQ technology, which has demonstrated in real-world studies improved time in range overnight and during the day4, Tandem Mobi connects with Dexcom G7 or Dexcom G6 to predict glucose levels 30 minutes in advance and automatically adjusts insulin, if needed, to help prevent highs and lows.
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
Ted Raad, Chief Executive Officer of Pulmatrix, commented, “MannKind’s interest in iSPERSE™ validates the enablement potential of our innovative particle engineering dry powder technology. In addition, the assumption of our lease and laboratory by MannKind helps extend our cash runway further into 2026. We are able to build upon this agreement to further support development of PUR3100 and its potential application with MannKind’s Cricket® device to develop the 1st orally inhaled DHE treatment for acute migraine.”
Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance
“We are thrilled with the DEA’s decision, which underscores the potential of MIRA-55 as a groundbreaking therapeutic candidate,” said Erez Aminov, Chairman & CEO of MIRA Pharmaceuticals. “This ruling allows us to focus on MIRA-55’s unique cognitive and anxiety benefits. With access to $90B traditional neurological and $30B cannabis markets, MIRA-55 represents a significant value proposition for our company. We remain committed to advancing it through the development pipeline for treating these diseases from which so many currently suffer.”
FundamentalVR Revolutionizes Surgical Training with Advanced AI Capabilities
“Our AI-driven approach marks a transformative shift in surgical training,” said Richard Vincent, Co-Founder and CEO at FundamentalVR. “By providing real-time insights and personalized guidance, Fundamental Surgery is revolutionizing how surgeons acquire and refine their skills, ultimately leading to safer and more effective patient care.”
Comprehensive Insights into Medical Device & Biotechnology Company Mergers, Acquisitions & Funding
Kazia Therapeutics Announces $2 Million Registered Direct Offering
Kazia has also agreed to issue in a concurrent private placement unregistered warrants to purchase up to an aggregate of 4,444,445 ADSs. The warrants will have an exercise price of $0.583 per ADS, will be immediately exercisable upon issuance, and will expire five and one-half years from the date of issuance. The closing of the offering is expected to occur on or about December 5, 2023, subject to the satisfaction of customary closing conditions.
Savage Medical Exits Stealth With Over $3 Million to Enable Minimally Invasive Colorectal Tumor Removal
The groundbreaking ColoSeal System™ enables minimally invasive colorectal tumor removal, eliminating the need for 2 open surgeries in today’s standard of care notes Savage Medical.
Industry Expert Byline
Reimagining CRM: What’s Next for Medtech Commercial Success | By Akshay Kapadia, CEO and Founder, Conexus Solutions, Inc.
Success depends on more than just choosing the right CRM platform; it requires aligning that platform with optimized business processes, a clear data strategy, and long-term commercial goals. When all of these elements work together, the CRM platform becomes a powerful tool to support growth, innovation, and sustained value.
FDA Medical Device Updates
Our Experts - Byline Articles
Advancements in Imaging
Philips Introduces Next-generation Digital Pathology Suite-IntelliSite
Philips Digital Pathology Suite – IntelliSite – features a comprehensive, scalable suite of software tools and capabilities designed to help streamline workflows, enhance diagnostic confidence, facilitate team collaboration, integrate artificial intelligence (AI) and increase the efficiency of pathology labs.
Medidata Rave Imaging Reaches Milestone, Supporting More Than 1,000 Clinical Studies
Rave Imaging, built on the Medidata Unified Platform, processes more than 100 million images annually.
Esaote Enters The World Of Total Body MRI With Magnifico Open
“In recent years, the technological evolution of MRI has seen major developments. At Esaote we have been working for over 30 years in the MRI sector to reach ever new horizons and 2021 is for us a year with a wealth of new products, confirming our constant commitment to innovation and the development of cutting-edge technologies,” commented Franco Fontana, Esaote CEO.
